Literature DB >> 9847433

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma.

Y Kohno1, K Minoguchi, N Oda, T Yokoe, N Yamashita, T Sakane, M Adachi.   

Abstract

BACKGROUND: Rush immunotherapy (RIT) has been shown to be effective in allergic asthma.
OBJECTIVE: We investigated the mechanisms of RIT on the basis of cytokine production by T-cell lines and airway inflammation and responsiveness.
METHODS: Subjects were 8 patients with house dust mite-allergic asthma treated with dust mite extract RIT for 6 months and 6 RIT-untreated control patients. IL-5 production by Dermatophagoides farinae -specific T-cell lines, eosinophil percentages, and eosinophil cationic protein (ECP) in induced sputum and airway responsiveness to allergen and histamine were evaluated before and after treatment. Changes in eosinophil percentages and ECP in induced sputum and responsiveness to histamine 24 hours after allergen inhalation were also studied.
RESULTS: After 6 months of RIT, percentages of total eosinophils (43. 0% +/- 6.90% to 16.8% +/- 2.48%; P <.01), percentages of EG2(+ ) eosinophils (32.6% +/- 6.39% to 19.7% +/- 4.68%; P <.01) and ECP (362.7 +/- 125.3 ng/mL to 26.2 +/- 5.15 ng/mL; P <.05) decreased in induced sputum, and IL-5 production by T-cell lines decreased (617 +/- 93.2 pg/mL to 200.0 +/- 34.1 pg/mL; P <.01). RIT decreased both early- and late-phase bronchoconstriction (early phase: 33.2% +/- 3. 46% to 25.4% +/- 1.42%; P <.03; late phase: 16.2% +/- 3.52% to 6.2% +/- 1.96%; P <.03) and suppressed increases in the percentages of total (61.8% +/- 4.89% to 42.0% +/- 4.67%; P <.01) and EG2-positive eosinophils (55.54% +/- 7.21% to 36.5% +/- 6.43%; P <.01) and ECP (685.6 +/- 217.0 ng/mL to 85.4 +/- 23.4 ng/mL; P <.05) in induced sputum after allergen inhalation. RIT also decreased airway responsiveness to dust mite (1:303.7 +/- 123.7 wt/vol to 1:65.0 +/- 13.2 wt/vol; P <.03) and to histamine before (397.1 +/- 206.9 microgra/mL to 1391.3 +/- 283.3 microgram/mL; P <.03) and after allergen inhalation (139.2 +/- 36.5 microgram/mL to 629.1 +/- 196.3 microgram/mL; P <.03).
CONCLUSION: RIT decreases airway inflammation and airway hyperresponsiveness before and after bronchial provocation with allergen, possibly by inhibiting both allergen-specific T-cell- and mast cell-dependent pathways. RIT is an effective antiinflammatory treatment in allergic asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9847433     DOI: 10.1016/s0091-6749(98)70330-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

Review 1.  Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations.

Authors:  Linda Cox
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

2.  Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study.

Authors:  Luis Prieto; Ricardo Palacios; Dulce Aldana; Anna Ferrer; Carmen Perez-Frances; Victoria Lopez; Rocio Rojas
Journal:  Allergy Asthma Clin Immunol       Date:  2010-09-16       Impact factor: 3.406

3.  Cough receptor sensitivity to capsaicin does not change after allergen bronchoprovocation in allergic asthma.

Authors:  H Minoguchi; K Minoguchi; A Tanaka; H Matsuo; N Kihara; M Adachi
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

4.  New approaches to managing asthma: a US perspective.

Authors:  William E Berger
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

Review 5.  Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews.

Authors:  Felix Asamoah; Artemisia Kakourou; Sangeeta Dhami; Susanne Lau; Ioana Agache; Antonella Muraro; Graham Roberts; Cezmi Akdis; Matteo Bonini; Ozlem Cavkaytar; Breda Flood; Kenji Izuhara; Marek Jutel; Ömer Kalayci; Oliver Pfaar; Aziz Sheikh
Journal:  Clin Transl Allergy       Date:  2017-08-02       Impact factor: 5.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.